Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PMDA’s Review-Related Ordinary Loss Nearly Doubled in FY2016
June 28, 2017
- MHLW Calls for Drafting Guidelines on Polypharmacy in the Elderly
June 27, 2017
- 6 APIs Added to List of “Switch OTC” Candidates: MHLW
June 26, 2017
- MHLW Redefines Drug Makers’ 3 Key Officer System
June 26, 2017
- Boxed Warning to Be Erased from Label of Pfizer Smoking Cessation Aid Champix
June 26, 2017
- Emergency Stockpile of Anti-Influenza Drugs to Be Reduced to Enough for 47.7 Million People
June 26, 2017
- 670 Codeine, Tramadol Medicines to Be Contraindicated for Kids under 12
June 23, 2017
- Wakayama Substance Supplier Mixed in China-Made Ingredient; MHLW Sees No Safety Concerns
June 23, 2017
- 3 Independent Administrative Agencies Will Have Access to Research Funding from Outside Initial Budgets
June 23, 2017
- Pharmaceuticals, Medical Devices Unlikely to Be Focus of Japan-EU EPA
June 22, 2017
- Draft Guideline on Lifecycle Management Reaches Agreement at ICH Meeting in Montreal
June 22, 2017
- JMA Plans Chuikyo Rep Reshuffle, Nakagawa Likely to Bow Out
June 21, 2017
- PMDA Beats FY2016 Review Time Targets
June 16, 2017
- CDISC-Based Electronic Submissions for 24 Products in FY2016: PMDA
June 16, 2017
- 15.3 Billion Yen to Be Allocated to 30 Projects to Promote R&D in Field of Healthcare
June 16, 2017
- MHLW Panel Recommends Moving Ahead with Discussions toward Easing Regulations on Export of Blood Products
June 16, 2017
- MHLW Tries to Give Full Picture of Envisaged “CEA” Scheme with Hypothetical Drug: Chuikyo
June 15, 2017
- 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
- Daiichi Sanko Espha Skips June Listing for Rezaltas, Gracevit AGs
June 15, 2017
- Chuikyo Reps Agree on Revisiting Discrepancy Rate Cutoff for Price Maintenance Premium
June 15, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…